Grifols closes 2 billion-euro bond issuance to finance Biotest buy

6 October 2021

Spanish plasma specialist Grifols (GRF:MC) says it has closed its issuance of senior unsecured notes for the equivalent of 2 billion euros ($2.32 billion) to finance its investment in Biotest AG.

The issuance, launched on September 27, 2021, closed in record time following the positive reaction of financial investors, who recognize and value the unique and transformational opportunity the Biotest investment represents for Grifols. This response also confirms the market's confidence in Grifols' business model.

Last month, Grifols proposed a 1.6 billion-euro takeover of its German rival Biotest (BIO: Xetra), in a move to consolidate the plasma-based drug industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK